Table 1.
Characteristics of subjects with prostate cancer (CaP) followed on active surveillance (AS) for primary treatment, stratified by race (N = 886).
| Race characteristic | Total | White | Black | P value |
|---|---|---|---|---|
| N = 886 | n = 696 | n = 190 | ||
| Age at diagnosis, years | <0.0001 | |||
| Mean (±SD)1 | 69.3 (±8.4) | 70.4 (±8.1) | 65.3 (±8.4) | |
| Median (range) | 70.2 (41.3–91.8) | 71.7 (41.3–91.8) | 65.6 (41.7–85.3) | |
| <60 | 109 (12.3) | 67 (9.6) | 42 (22.1) | |
| 60–60.9 | 324 (36.6) | 232 (33.3) | 92 (48.4) | |
| ≥70 | 453 (51.1) | 397 (57.0) | 56 (29.5) | |
| PSA at diagnosis, ng/mL, N (%) | <0.0001 | |||
| <10 | 607 (68.5) | 499 (71.7) | 108 (56.8) | |
| 10–19.99 | 153 (17.3) | 115 (16.5) | 38 (20.0) | |
| ≥20 | 126 (14.2) | 82 (11.8) | 44 (23.2) | |
| Comorbidities, N (%) | 0.1793 | |||
| 0 | 231 (26.1) | 187 (26.9) | 44 (23.2) | |
| 1 | 264 (29.8) | 205 (29.4) | 59 (31.0) | |
| 2 | 198 (22.3) | 146 (21.0) | 52 (27.4) | |
| ≥3 | 193 (21.8) | 158 (22.7) | 35 (18.4) | |
| Clinical T stage, N (%) | 0.1260 | |||
| T1-T2a | 660 (74.5) | 520 (74.7) | 140 (73.7) | |
| T2b | 96 (10.8) | 82 (11.8) | 14 (7.4) | |
| T2c | 68 (7.7) | 49 (7.0) | 19 (10.0) | |
| T3-4 | 62 (7.0) | 45 (6.5) | 17 (8.9) | |
| Biopsy grade, N (%) | 0.1806 | |||
| 2–6 | 646 (72.9) | 517 (74.3) | 129 (67.9) | |
| 7 | 168 (19.0) | 127 (18.2) | 41 (21.6) | |
| 8–10 | 72 (8.1) | 52 (7.5) | 20 (10.5) | |
| D'Amico et al. risk strata, N (%) | 0.0023 | |||
| Low | 434 (49.0) | 359 (51.6) | 75 (39.5) | |
| Intermediate | 228 (25.7) | 178 (25.6) | 50 (26.3) | |
| High | 224 (25.3) | 159 (22.8) | 65 (34.2) | |
| Secondary treatment type, N (%) | <0.0001 | |||
| None (AS only) | 401 (45.3) | 333 (47.8) | 68 (35.8) | |
| RP2 | 125 (14.1) | 87 (12.5) | 38 (20.0) | |
| EBRT-Br3 | 192 (21.7) | 134 (19.2) | 58 (30.5) | |
| HT4 | 168 (19.0) | 142 (20.4) | 26 (13.7) | |
| Time from Dx5to secondary treatment, months | 0.0135 | |||
| Mean (±SD) | 30.6 (±26.6) | 32.7 (±28.5) | 24.5 (±18.6) | |
| Median (range) | 19.6 (9.0–149.6) | 20.3 (9.0–149.6) | 16.0 (9.0–92.0) | |
| Followup, years | 0.4641 | |||
| Mean (±SD) | 6.1 (±4.0) | 6.1 (±4.0) | 5.8 (±3.7) | |
| Median (range) | 5.2 (0.8–17.2) | 5.2 (0.8–17.2) | 5.4 (0.8–16.8) |
1SD: standard deviation.
2RP: radical prostatectomy.
3EBRT-BR: external beam radiation therapy and Brachytherapy, combined.
4HT: hormone therapy.
5Dx: diagnosis of CaP.